In brief: Cytopia, Visiomed
Wednesday, 27 April, 2005
Cytopia (ASX:CYT) has received ethics approval to begin a Phase I clinical trial of its anti-cancer drug CYT997 at at the Royal Brisbane and Women's Hospital. The trial will be conducted in association with the Queensland Institute of Medical Research and Q-Pharm. Cytopia chief scientific officer Andrew Wilks said that the 30-patient trial would be a non-blinded, dose escalation study in patients with various cancers and could take between nine and twelve months.
Visiomed has received an initial purchase order for approximately 1500 Funhaler asthma spacers from its Australian distributor, Cottman Australia, a subsidiary of Advance Healthcare Group Limited (ASX:AHG). The order will take up 100 per cent of the Visiomed's first production run.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
